

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.

11068-065-999

APPLICATION NO

10/612,603

APPLICANT

Chappey *et al.*

FILING DATE

July 1, 2003


GROUP

1646

**U.S. PATENT DOCUMENTS**


*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HH	A01	5,436,131	7/25/95	Condra <i>et al.</i>			
	A02	5,837,464	11/17/98	Capon <i>et al.</i>			
	A03	6,033,902	3/7/00	Haseltine <i>et al.</i>			
	A04	6,103,462	8/15/00	Paulous <i>et al.</i>			
↓	A05	6,242,187	6/5/01	Capon <i>et al.</i>			


**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUBCLA SS	TRANSLAT ION	
							YES	NO
HH	A06	WO99/67427	6/99	PCT				
HH	A07	Int'l Search Report for PCT/US03/21335	5/3/04	PCT				

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

HH	A08	Condra <i>et al.</i> , (1996), "Genetic Correlates of In Vivo Resistance to Indinavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor," <i>Journal of Virology</i> , 70(12): 8270-76
	A09	Genbank Accession Number AF324493 HIV-1 vector pNL4...[gi:12831134] (2001).
	A10	Gervaix <i>et al.</i> , (1997), "A New Reporter Cell Line to Monitor HIV Infection and Drug Susceptibility <i>in Vitro</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 94:4653-4658.
	A11	Gong <i>et al.</i> , (2000), "In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632," <i>Antimicrobial Agents and Chemotherapy</i> , 44(9): 2319-26.
	A12	Gunthard <i>et al.</i> , (1998), "Comparative Performance of High-Density Oligonucleotide Sequencing and Dideoxynucleotide Sequencing of HIV Type 1 <i>pol</i> From Clinical Samples", <i>Aids Research and Human Retroviruses</i> , 14(10): 869-876.
	A13	Haubrich <i>et al.</i> , (2001), "CCTG 575: A Randomized, Prospective Study of Phenotype Testing Versus Standard of Care For Patients Failing Antiretroviral Therapy," <i>Antiviral Therapy</i> , 6(Supplement 1): 63.
	A14	Herrmann <i>et al.</i> , (1997), "A Working Hypotheses-Virus Resistance Development As An Indicator of Specific Antiviral Activity," <i>Ann. NY Acad Sciences</i> , 284: 632-637.
	A15	Hertogs <i>et al.</i> , (1998), "A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates From Patients Treated with Antiretroviral Drugs," <i>Antimicrobial Agents and Chemotherapy</i> , 42(2): 269-276.
	A16	Hirsch <i>et al.</i> , (2000), "Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection," <i>JAMA</i> , 283(18): 2417-26.
	A17	Katzenstein <i>et al.</i> , (2002), "Baseline Phenotypic Susceptibility and Virologic failure over 144 weeks Among Nucleoside RT Inhibitor Experienced Subjects in ACTG 364," Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection," 2002 9 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Session 77 Poster Session 591-T.
	A18	Katzenstein <i>et al.</i> , (2002), "The Inhibitory Quotient (IQ) for Saquinavir (SQV) Predicts Virologic Response to Salvage Therapy," 2002 9 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Session 28 Poster Session 129.
	A19	Maguire <i>et al.</i> , (2002), "Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors," <i>Antimicrobial Agents and Chemotherapy</i> , 46(3): 731-738.
↓	A20	Petropoulos <i>et al.</i> , (2000), "A Novel Phenotypic Drug Susceptibility Assay For Human Immunodeficiency Virus Type 1," <i>Antimicrobial Agents and Chemotherapy</i> , 44(4): 920-928.

HA	A21	Race <i>et al.</i> , (1999), "Analysis of HIV Cross-Resistance to Protease Inhibitors Using A Rapid Single-Cycle Recombinant Virus Assay For Patients Failing On Combination Therapies," <i>AIDS</i> , 13(15): 2061-2068.
I	A22	Schuurman <i>et al.</i> , (1999), "Worldwide Evaluation of DNA Sequencing Approaches for Identification of Drug Resistance Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase," <i>Journal of Clinical Microbiology</i> , 37(7): 2291-2296.
↓	A23	Shi <i>et al.</i> , (1997), "A Recombinant Retroviral System for Rapid In Vivo Analysis of Human Immunodeficiency Virus Type 1 Susceptibility to reverse Transcriptase Inhibitors," <i>Antimicrobial Agents and Chemotherapy</i> , 41(12): 2781-85.
EXAMINER		DATE CONSIDERED
		2/1/2006
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		



# LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

ATTY DOCKET NO.  
11068-065-999

APPLICATION NO  
10/612,603

APPLICANT  
Chappey *et al.*

FILING DATE  
July 1, 2003

GROUP  
1645

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HH	B01	5,766,842	6/98	Melnick <i>et al.</i>			
	B02	20020064838	5/02	Parkin <i>et al.</i>			
	B03	20030108857	6/03	Parkin <i>et al.</i>			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
HH	B04	WO00/78996	12/00	PCT				
	B05	WO02/22076	3/02	PCT				
	B06	WO02/068618	9/02	PCT				
	B07	WO02/099387	12/02	PCT				
	B08	WO03/070700	8/03	PCT				
	B09	WO04/003512	1/04	PCT				
	B10	WO04/003514	1/04	PCT				
	B11	Int'l Search Report for PCT/US00/17178	12/00	PCT				
	B12	Int'l Search Report for PCT/US01/28754	3/02	PCT				
	B13	Int'l Search Report for PCT/US02/01682	9/02	PCT				
	B14	Int'l Search Report for PCT/US02/18684	1/03	PCT				
	B15	Int'l Search Report for PCT/US03/04362	12/04	PCT				
	B16	Int'l Search Report for PCT/US03/21023	7/04	PCT				

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)


HH	B17	Carrillo <i>et al.</i> , (1998), "In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants With Increased Resistance to ABT-378, a Novel Protease Inhibitor," <i>Journal of Virology</i> , 72(9): 7532-41.
	B18	Craig <i>et al.</i> , 1998 "HIV Protease Genotype and Viral Sensitivity to HIV Protease Inhibitors Following Saquinavir Therapy", <i>AIDS</i> , 12: 1611-1618.
	B19	Dreyer GB, <i>et al.</i> "A Symmetric Inhibitor Binds HIV-1 Protease Asymmetrically" <i>Biochemistry</i> (1993) 32:937-947
	B20	J. Eron, <i>et al.</i> , (1995) Preliminary Assessment of 141 W94 in Combination with Other Protease Inhibitors," <i>5th Conference on Retroviruses and Opportunistic Infections</i> :
	B21	Genbank Accession Number P12497 POL Polyprotein (2004)
	B22	Hazuda, <i>et al.</i> , 2000 "Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells," <i>Science</i> 287: 646-650.



B23	Hill, A. <i>et al.</i> (1998) "Low frequency of genotypic mutations associated with resistance to AZT and 3TC after combination treatment with indinavar," <i>Int. Conf. AIDS</i> 12:812, (Abstract No. 6)
B24	Kempf <i>et al.</i> , (2001), "Identification of Genotypic Changes in Human Immunodeficiency Virus Protease that Correlate With Reduced Susceptibility to the Protease Inhibitor Lopinavir Among Viral Isolates From Protease Inhibitor-Experienced Patients," <i>Journal of Virology</i> , 75(16): 7462-69.
B25	Kim, (1995) " Crystal Structure of HIV-1 Protease in Complex with VX-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme," <i>J. Am. Chem. Soc.</i> , 117: 1181-1182
B26	Lambert DM, <i>et al.</i> (1992) "Human Immunodeficiency Virus Type 1 Protease Inhibitors Irreversibly Block Infectivity of Purified Virions From Chronically Infected Cells" <i>Antimicrob Agents Chem</i> 36:982-98
B27	Larder, <i>et al.</i> , (1995) "Potential Mechanism for; Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy," <i>Science</i> , 269; 696-699
B28	Lazdins, <i>et al.</i> , (1997) "In Vitro Effect of al-Acid Glycoprotein on the Anti-Human Immunodeficiency Virus (HIV) Activity of the Inhibitor CGP 61775: A Comparative Study with Other Relevant HIV Protease Inhibitors," <i>J Infect. Dis.</i> , 175: 1063-1070
B29	Livingston, <i>et al.</i> , (1995) "Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus Therapy," <i>J Infect. Dis.</i> , 172:1.238-124
B30	Mahalingam, <i>et al.</i> , (1999) "Structural and Kinetic Analysis of Drug Resistant Mutants of HIV Protease," <i>Biochem.</i> , 263: 1-9
B31	Miller M, <i>et al.</i> (1989) "Structure of Complex of Synthetic HIV-1j Protease with a SubstrateBased Inhibitor at 2.3 A Resolution," <i>Science</i> 246:1149-1152
B32	Mohri H, <i>et al.</i> (1993) "Quantitation of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 in the Blood of Treated and Untreated Patients," <i>PNAS</i> 90:25-29
B33	Murphy, <i>et al.</i> , (1999) "Treatment with Amprenavir Alone or Amprenavir with Zidovudine and Lamivudine in Adults with Human Immunodeficiency Virus Infection" <i>J. Infect. Dis.</i> , 179: 808-81 E
B34	Najera I, <i>et al.</i> (1994) "Natural Occurrence of Drug Resistance Mutations in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Isolates," <i>Aids Res Hum Retroviruses</i> 10:1479-1488
B35	Najera I, <i>et al.</i> (1995) "pol Gene Quasispecies of Human Immunodeficiency Virus: Mutations Associated with Drug Resistance in Virus From Patients Undergoing No Drug Therapy," <i>J Virol</i> 69:23-31
B36	Palmer, <i>et al.</i> , (1999) "Highly Drug-resistant HIV-1 Clinical Isolates Are Cross-resistant to Many Antiretroviral Compounds in Current Clinical Development," <i>AIDS</i> , 13: 661-667
B37	Parkin, <i>et al.</i> , (1999) "Phenotypic changes in Drug Susceptibility Associated with Failure of Human Immunodeficiency Virus Type 1 (HIV-1) Triple Combination Therapy," <i>J Infect. Dis.</i> , 180: 865-870
B38	Partaledis, <i>et al.</i> , (1995) "In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Isolates with Reduced Sensitivity to Hydroxyethylamino Sulfonamide Inhibitors of HIV-1 Aspartyl Protease," <i>Journal of Virology</i> , 69: 5228-5235
B39	Patick, <i>et al.</i> , (1998) "Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir," <i>Antimicrobial Agents and Chemotherapy</i> , 42(10): 2637-44.
B40	Petit SC, <i>et al.</i> (1993) "The Specificity of the HIV-1 Protease" <i>Drug Discov Des</i> 1:69-83
B41	Roberts NA, <i>et al.</i> (1990) "Rational Design of Peptide-Based HIV Proteinase" <i>Science</i> 248:358361
B42	Roberts, N. A., (1995) "Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors," <i>AIDS</i> 9 (supp 2) S27-S32
B43	Rusconi, Stefano. <i>et al.</i> (2000): "Susceptibility to PNU-140690 (Tipranavir) of Human Immunodeficiency Virus Type 1 Isolates Derived From Patients with Multidrug Resistance to Other Protease Inhibitors," <i>Antimicrobial Agents and Chemotherapy</i> , 44(5): 1328-32.
B44	Sadler, <i>et al.</i> , (1999) "Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, Following Oral Administration of Single Doses to HIV-Infected Adults," <i>Antimicrobial Agents and Chemotherapy</i> , 43: 1686-1692
B45	Sarkar, <i>et al.</i> , (1990) "The "Megaprimer" Method of Site-Directed Mutagenesis," <i>BioTech</i> 8(4):404-407
B46	Smidt, <i>et al.</i> , (1996) "A Mutation in Human Immunodeficiency Virus Type 1 Protease at Position 88, Located Outside the Active Site, Confers Resistance to the Hydroxyethylurea Inhibitor SC-55389A," <i>Antimicrobial Agents and Chemotherapy</i> , 41: 515-522
B47	St. Clair, <i>et al.</i> , (1996) "In Vitro Antiviral Activity of 141 W94 (VX-478) in Combination with Other Antiretroviral Agents," <i>Antiviral Research</i> 29: 53-56
B48	Tian, <i>et al.</i> , (1998) "Zidovudine/Lamivudine Co-resistance Is Preceded by a Transient Period of Zidovudine Hypersensitivity," 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Abstract 30
B49	Tisdale, M. <i>et al.</i> (1998): "Genotypic and phenotypic analysis of HIV from patients on ZDV/3TC/amprenavir combination therapy," <i>Int. Conf AIDS</i> 12:583 (Abstract No. 32312)
B50	Tisdale, M. <i>et al.</i> (1995): "Cross-Resistance Analysis of Human Immunodeficiency Virus Type 1 Variants Individually Selected for Resistance to Five Different Protease Inhibitors," <i>Antimicro. Agents and Chemo.</i> 39(8):1704-10.
B51	Tucker, <i>et al.</i> , (1998) "Estimate of the Frequency of Human Immunodeficiency Virus Type 1 Protease Inhibitor Resistance Within Unselected Virus Populations In Vitro," <i>Antimicrobial Agents and Chemotherapy</i> , 42: 478-480



B52	Young <i>et al.</i> J. Infect. Disease 178(5) 1497-1501 (1998)		
B53	Ziermann, <i>et al.</i> , (2000), "A Mutation in Human Immunodeficiency Virus Type 1 Protease, N88S, That Causes In Vitro Hypersensitivity to Amprenavir," <i>Journal of Virology</i> , 74(9): 4414-4419.		
EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	2/1/2006
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.

11068-065-999

APPLICATION NO

10/612,603

APPLICANT

Chappey *et al.*

FILING DATE

July 1, 2003

GROUP

1645

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

CH	C01	Andrew Chin, March 9, 2002, "On the Preparation and Utilization of Isolated and Purified Oligonucleotides" (Paper Copy and CD-ROM included)
----	-----	---

EXAMINER

DATE CONSIDERED

2/1/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.